Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 12/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 10/20 | 1.00 |
| ▸ | STAT5A | P42229 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 9/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.79 |
| ▸ | KIT | P10721 | 3/20 | 0.79 |
| ▸ | WEE1 | P30291 | 3/20 | 0.73 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.73 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.73 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.73 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.70 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.70 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.70 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.70 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30257377 | 1.00 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL29765306 | 1.00 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL256711 | 1.00 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL1334768 | 0.88 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL5764062 | 0.88 | FGFR1 (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL5762046 | 0.87 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL5764012 | 0.87 | FGFR1 (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL13498143 | 0.86 | FGFR1 (0.83) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL1249524 | 0.85 | FGFR1 (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL28558346 | 0.85 | FGFR1 (0.74) | SRCFGFR1EGFRPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20250360129-A1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-11-27 | — | — | US | claimed |
| EP-3250192-B1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-10-08 | — | — | EP | claimed |
| US-20240398799-A1 | COMPOSITIONS AND METHODS FOR GENERATING SYNTHETIC LETHALITY IN TUMORS | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2024-12-05 | — | — | US | claimed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | claimed |
| US-20230149415-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-05-18 | — | — | US | claimed |
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| US-20230078425-A1 | COMPOSITIONS AND METHODS FOR GENERATING SYNTHETIC LETHALITY IN TUMORS | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-03-16 | — | — | US | claimed |
| US-20230073494-A1 | COMPOSITIONS AND METHODS FOR GENERATING SYNTHETIC LETHALITY IN TUMORS | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-03-09 | — | — | US | claimed |
| EP-4127722-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2023-02-08 | — | — | EP | claimed |
| US-20230036788-A1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2023-02-02 | — | — | US | claimed |
| WO-2022182982-A1 | METHODS FOR TREATING C-KIT KINASE MEDIATED DISEASES AND DISORDERS USING A SELECTIVE C-KIT KINASE INHIBITOR | THIRD HARMONIC BIO, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-11324747-B2 | Methods and compositions for managing neuroinflammation and neurodegeneration | CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS (IN) | 2022-05-10 | — | — | US | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-3946360-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| WO-2022027058-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | SRC 1660/4885FGFR1 3094/4885EGFR 1098/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | SRC 10/4885FGFR1 709/4885EGFR 157/4885 |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | GLS, GLUL, GLS2 | SRC 4841/4885FGFR1 2508/4885EGFR 970/4885 |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | SRC 1142/4885FGFR1 595/4885EGFR 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.